My Learning Cart
?
Categories
Account

Which biotech company received FDA approval for a gene therapy targeting a rare

₹0.0
Login to Download
  • 📥 Instant PDF Download
  • ♾ Lifetime Access
  • 🛡 Secure & Original Content

What’s inside this PDF?

Question: Which biotech company received FDA approval for a gene therapy targeting a rare genetic disorder in 2022?

Options:

  1. Bluebird Bio
  2. Novartis
  3. Sarepta Therapeutics
  4. Spark Therapeutics

Correct Answer: Spark Therapeutics

Solution: 

Spark Therapeutics received FDA approval for its gene therapy targeting a rare genetic disorder, showcasing advancements in biotech applications.

Which biotech company received FDA approval for a gene therapy targeting a rare

Practice Questions

Q1
Which biotech company received FDA approval for a gene therapy targeting a rare genetic disorder in 2022?
  1. Bluebird Bio
  2. Novartis
  3. Sarepta Therapeutics
  4. Spark Therapeutics

Questions & Step-by-Step Solutions

Which biotech company received FDA approval for a gene therapy targeting a rare genetic disorder in 2022?
  • Step 1: Identify the year in question, which is 2022.
  • Step 2: Look for biotech companies that received FDA approval in 2022.
  • Step 3: Focus on gene therapies that target rare genetic disorders.
  • Step 4: Find the specific company that received this approval.
  • Step 5: Confirm that Spark Therapeutics is the company that received FDA approval for its gene therapy.
No concepts available.
Soulshift Feedback ×

On a scale of 0–10, how likely are you to recommend The Soulshift Academy?

Not likely Very likely
Home Practice Performance eBooks